These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10877036)

  • 1. An ABC of drug-related problems.
    Meyboom RH; Lindquist M; Egberts AC
    Drug Saf; 2000 Jun; 22(6):415-23. PubMed ID: 10877036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational pharmacotherapy and pharmacovigilance.
    Akici A; Oktay S
    Curr Drug Saf; 2007 Jan; 2(1):65-9. PubMed ID: 18690951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of Vigimed, a global e-mail system for the exchange of pharmacovigilance information.
    Johansson K; Olsson S; Hellman B; Meyboom RH
    Drug Saf; 2007; 30(10):883-9. PubMed ID: 17867725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Veterinary pharmacovigilance in India: A need of hour.
    Kumar R; Kalaiselvan V; Verma R; Kaur I; Kumar P; Singh GN
    Indian J Pharmacol; 2017; 49(1):2-3. PubMed ID: 28458414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Principles of signal detection in pharmacovigilance.
    Meyboom RH; Egberts AC; Edwards IR; Hekster YA; de Koning FH; Gribnau FW
    Drug Saf; 1997 Jun; 16(6):355-65. PubMed ID: 9241490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of legal warnings after drug approval in Thailand.
    Sriphiromya P; Theeraroungchaisri A
    Regul Toxicol Pharmacol; 2015 Feb; 71(1):108-13. PubMed ID: 25445000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updating the French method for the causality assessment of adverse drug reactions.
    Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB;
    Therapie; 2013; 68(2):69-76. PubMed ID: 23773347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacovigilance: a necessary tool].
    Coêlho HL
    Cad Saude Publica; 1998; 14(4):871-5. PubMed ID: 9878921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the dose, time, susceptibility (DoTS) classification scheme for adverse drug reactions in pharmacovigilance planning.
    Callréus T
    Drug Saf; 2006; 29(7):557-66. PubMed ID: 16808549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal selection and follow-up in pharmacovigilance.
    Meyboom RH; Lindquist M; Egberts AC; Edwards IR
    Drug Saf; 2002; 25(6):459-65. PubMed ID: 12071784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions.
    Hauben M; Horn S; Reich L
    Drug Saf; 2007; 30(2):143-55. PubMed ID: 17253879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic ineffectiveness: heads or tails?
    Figueras A; Pedrós C; Valsecia M; Laporte JR
    Drug Saf; 2002; 25(7):485-7. PubMed ID: 12093306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The monitoring medicines project: a multinational pharmacovigilance and public health project.
    Pal SN; Olsson S; Brown EG
    Drug Saf; 2015 Apr; 38(4):319-28. PubMed ID: 25829215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of reporting therapeutic ineffectiveness as an adverse drug reaction.
    Meyboom RH; Lindquist M; Flygare AK; Biriell C; Edwards IR
    Drug Saf; 2000 Aug; 23(2):95-9. PubMed ID: 10945372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study.
    Schutte T; Tichelaar J; Reumerman MO; van Eekeren R; Rolfes L; van Puijenbroek EP; Richir MC; van Agtmael MA
    Drug Saf; 2017 May; 40(5):409-418. PubMed ID: 28120270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance and post-black market surveillance.
    Langlitz N
    Soc Stud Sci; 2009 Jun; 39(3):395-420. PubMed ID: 19848184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmarketing surveillance of adverse drug reactions: problems and solutions.
    Lortie FM
    CMAJ; 1986 Jul; 135(1):27-32. PubMed ID: 3719483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discussing basic principles for a coding system of drug-related problems: the case of PI-Doc.
    Schaefer M
    Pharm World Sci; 2002 Aug; 24(4):120-7. PubMed ID: 12227243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.